Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 300: sotorasib + panitumumab versus investigator's choice in previously treated KRAS G12C-mutant metastatic colorectal cancer
2024-511187-81-00Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Sotorasib + panitumumab, Investigator's choice: trifluridine + tipiracil and Investigator's choice: regorafenib (3 arms). Primary endpoint: Progression-free survival. Started Oct 2024; status: completed.
02
Drugs
sotorasibpanitumumabtrifluridine + tipiracilregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-511187-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511187-81-00.